Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
2,240 total articles
Warner Bros. Discovery's announced tie-ups and breakup dynamics have created a narrow window where a well-capitalized buyer or asset manager - call it Versant - can extract value from divested brands and rights. At $28.18, WBD offers a leveraged, cash-flowing media business trading below takeover multiples and above its 2025 trough. This note lays …
CoreWeave has grown into a multi-billion revenue machine with a blockbuster contracted backlog and a massive 2026 capex plan. The stock looks attractively valued for a high-growth cloud infrastructure name trading under $80, but heavy leverage, steep cash burn, and pending litigation make execution the primary risk. This trade idea lays out an entr…
L.B. Foster (FSTR) sold off intraday but fundamentals and a cleaner balance sheet support a mid-term long trade. Entry $31.66, stop $28.70, target $36.00 over ~45 trading days. Key drivers: positive free cash flow ($27.7M), improved credit facility, and technical support near the 50-day average.
Accenture (ACN) has been sold down amid AI job-displacement headlines and macro noise. The pullback leaves a high-quality services franchise trading at attractive multiples, with $11.5B in free cash flow, a 3%+ yield and a conservative balance sheet. This is a tactical long idea sized for a mid-term swing: entry $206.00, stop $188.73, target $260.0…
Post Holdings is trading at a modest multiple against steady cash generation and an EV/EBITDA of 9.6x. Management's mix of acquisitions and shareholder returns, plus industry resilience, create an asymmetric opportunity. Upgrade to long with an explicit entry, stop and target and a 180-trading-day time horizon.
ACI Worldwide is a cash-generative payments-software provider sitting squarely in the crosshairs of three structural trends: real-time payments, open banking, and AI-driven transaction monitoring. At roughly $4.2B market cap and trading at ~18.6x earnings with FCF of $309.9M, the stock offers a favorable risk-reward for a long-term trade while mana…
Sea Limited plunged after margin concerns and a bookings hiccup in gaming spooked investors on 03/03/2026. That sell-off pushed the stock to a fresh 52-week low intraday and into oversold territory (RSI 26.7), while short interest has been falling and volumes spiked. We view the Shopee competition narrative as overblown relative to Sea's multi-segm…
Nvidia's data-center GPU franchise is uniquely positioned to capture a spike in defense and national-security AI demand. The stock trades near $180 with a market cap above $4.4 trillion but continues to generate enormous free cash flow and double-digit revenue growth. This note lays out a mid-term trade (45 trading days) to take advantage of geopol…
Paycom (PAYC) looks like a classic turnaround-with-optional-reward setup: deeply discounted multiples relative to prior highs, $408M in free cash flow and no debt, accelerating buybacks, and solid profitability despite decelerating growth. This trade targets a meaningful multiple re-rating while keeping a protective stop under structural support.
ITA sits inside a politically charged rally: strong aerospace order trends, consolidation among parts suppliers and a proposed jump in U.S. defense spending have pushed the ETF near its 52-week high. With technical momentum (RSI ~59.6, bullish MACD) and market cap of $16.09B, this is a disciplined buy for investors willing to accept policy and head…
Cheniere Energy Partners (CQP) looks positioned to benefit from renewed LNG market tightness. With a $30B market cap, $2.53B of free cash flow and a clean balance between cash generation and distributable cash, we're upgrading CQP to a tradeable buy for swing traders. The technicals and shorter-term momentum support a push toward the 52-week high, …
Credo Technology fell sharply after a solid quarter and upbeat guidance. The pullback takes valuation from frothy toward more defensible levels, RSI is oversold, and high-frequency data-center demand gives a clear growth runway. This trade targets a bounce back to $140 within ~45 trading days, with a disciplined stop below $85 to limit downside ris…
Trinity Capital offers a compelling risk-reward here: a roughly 13.7% cash yield, P/E in the high single digits, and a market cap around $1.2B. We upgrade TRIN to a buy and outline a mid-term (45 trading days) trade with clear entry, stop and target that respects the BDC's leverage and cyclical exposure.
Ascendis Pharma (ASND) just received FDA accelerated approval for YUVIWEL (navepegritide), the first once-weekly treatment for children with achondroplasia. The approval and an early-Q2 2026 commercial roll-out create a clear near-term revenue catalyst. Technicals and volume show bullish momentum, but litigation and market competition mean position…
Cheniere Energy (LNG) is a market leader in U.S. LNG exports with an asset base and contract profile that benefits directly from global supply disruptions. With market cap near $53.3B, EV ~$72.2B, and free cash flow around $2.22B, the stock combines tangible cash generation with bullish technicals. This trade idea lays out an actionable swing trade…
Super Micro Computer (SMCI) has been punished for margin volatility even as top-line demand from AI infrastructure remains torrid. The stock’s valuation is constructive on sales multiples, short interest is elevated, and recent technicals show a base near the low-$30s. We lay out a mid-term, defined-risk long with a clear entry, stop and $45 target…
Banc of California (BANC) is trading below tangible book and yields a modest cash dividend while free cash flow and recent earnings show the bank can fund buybacks and loan sales. With the stock near $18, an entry at $18.00, a stop at $16.00 and a target at $21.50 sets up a risk-managed long that plays rate tailwinds, CRE repositioning, and a posit…
Hims & Hers (HIMS) has been hammered by regulatory and legal setbacks around copycat GLP-1 offerings, but underlying telehealth, dermatology and sexual health businesses still show growth and management is betting on international expansion via a $1.15B Eucalyptus acquisition. The stock trades at about $15.31 with a $3.49B market cap, attractive te…
GE Vernova is uniquely positioned to capture the electricity-infrastructure surge driven by AI data centers. Backlogs in gas turbines, a transformer-focused Prolec GE deal and accelerating electrification projects point to outsized revenue visibility. I’m raising my tactical price target to $980 and presenting a mid-term long trade: entry $820, sto…
Global Ship Lease (GSL) is a contained, cash-generating charter owner of 69 containerships. With $1.92B of contracted revenue and an average remaining charter term of 2.5 years, the company looks poised to benefit from rising 2026 geopolitical frictions that favor fixed, long-term charters. We outline a long trade with an entry at $39.05, a $50.00 …
Micron sits at the center of the AI memory supercycle. With a market cap north of $426B, strong profitability (ROE ~20%), and constrained high-bandwidth memory supply, the upside to $1,000 is plausible if revenue and margins continue to scale. This is a long-term trade idea: enter at $378.6465, target $1,000, stop at $320. The trade leans on contin…
X4 Pharmaceuticals (XFOR) is a small-cap biotech with an FDA-marketed drug (mavorixafor / XOLREMDI) and a funded development program to expand that label into chronic neutropenic disorders. The company has raised meaningful capital, secured an EU commercialization partner with milestone upside, and is trading at a market cap (~$290M) that leaves ro…
New Found Gold (NFGC) is a development-stage gold company trading at about $888M market cap. Recent drill success, a sizable strategic stake from Dundee, and still-elevated short interest create an asymmetric risk/reward: a successful delivery of resource and de-risking catalysts could drive valuation toward multi-billion-dollar developer levels. T…
Pfizer is trading near the top of its 52-week range but still offers a compelling income-plus-upside trade. The combination of roughly $10.4B in annual free cash flow, a 6.3% dividend yield, modest leverage and a developing oral GLP-1 program supports a mid-term re-rating. We lay out an actionable swing trade with entry, stop and target, plus catal…
Arcus reported a quarterly beat and the casdatifan program has shown enough signal to keep investors focused. The stock trades around $22.42 with a market cap near $2.8B and high short interest; that combination creates a tactical long opportunity with a clearly defined entry at $22.50, stop at $20.00 and a $26.00 target over a mid-term 45 trading …
